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Dosimetric Evaluation of Tumor Tracking 
in 4D Radiotherapy
Purpose
In some patients the tumors in lung, pancreas, liver, breast, and other 
organs move significantly during cardiac and breathing cycles. In this 
study we have investigated the dosimetric benefits of real-time tumor 
tracking for patients who were diagnosed with lung cancer.
Materials and Methods
The study includes the evaluation of dosimetric advantages of tumor 
motion tracking and the irradiation of normal lung and spinal 
cord. The dosimetric evaluation of tumor tracking was carried out 
on ten randomly selected patients who were scanned using 4D-CT 
technique. The 4D-CT phase reconstruction was performed using GE 
Advantage Workstation software, version AW 4.3_07. The 3D-CRT 
plans were generated using CMS-XiO4.4. Tissue heterogeneity was 
corrected for all plans. For each patient, eleven dosimetric plans were 
generated: ten plans for the target volumes contoured at ten breathing 
phases and one plan for the internal target volume (ITV) generated 
on average intensity projection (AvIP) studyset. The ITV was defined 
as a spatial sum of the gross target volumes (GTV) for each phase. 
The phasewise plans were compared to the clinically used ITV-AvIP 
plans in order to assess dosimetric effects of tumor tracking. The 
planning target volumes (PTV) were generated by adding 10mm 
margin around GTVs and ITV for both phase-wise plans and ITV-
AvIP plans. To analyze data obtained from the dosimetric plans we 
compared dosimetric parameters including coverage of PTV (D99, 
D95, D50) volumes of normal lung receiving 5Gy, 13Gy, 20Gy, 30Gy 
dose (V5, V13, V20, V30) and D5 of spinal cord for AvIP-based plans 
with phase-wise tracked plans.
Results
Average PTV coverages for all plans were 91.6% of the prescribed 
dose (PD) for D99, 96.7% for D95 and 104.3% for D50. The average 
maximum dose was 110% of PD and the mean dose was 103.6% of 
PD. The 3D tumor motions for all investigated patients were more 
than 10mm. It was observed that average V5, V13, V20 and V30 with 
tracking technique were about 17.4%, 19.3%, 18.3% and 22.7% lower 
than the Vxs without tracking, respectively. Approximately 20% 
of healthy lung received 4-8Gy less dose when the tumor tracking 
technique was used. Spinal cord was the most important critical organ 
for the studied lung cases. Dose to the spinal cord (D5) with tracking 
technique was 17.5% lower compared to that of without tracking. D5 
of the spinal cord received approximately 0.5-11 Gy less dose when 
tumor tracking technique was used; wide variations were observed 
due to differences in prescribed dose, tumor location and size.
Conclusion
Implementation of the active tracking and dynamic dose delivery 
techniques can potentially improve dose distribution of the tumor-
volumes. This, in turn, will potentially improve the quality of patient 
treatment by minimizing irradiation to the healthy tissues, sparing 
critical organs and lowering the toxicities.
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